Stay updated on Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.

Latest updates to the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a phase II trial for ixazomib citrate in treating relapsed multiple myeloma, while adding new identifiers and a revision number.SummaryDifference44%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
- Check36 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a more recent last update date (2025-03-25), replacing the previous version (v2.14.2) and date (2025-02-13).SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check80 days agoChange DetectedThe webpage has updated its date references, removing older dates and adding new ones for February 2025. This indicates a shift in the timeline of the content presented.SummaryDifference0.5%
Stay in the know with updates to Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.